Cimalgex

RSS

cimicoxib

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 14/01/2016

Authorisation details

Product details
Name
Cimalgex
Agency product number
EMEA/V/C/000162
Active substance
cimicoxib
International non-proprietary name (INN) or common name
cimicoxib
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QM01AH93
Publication details
Marketing-authorisation holder
Vétoquinol SA
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
18/02/2011
Contact address
Magny-Vernois
F-70 200 Lure
France

Product information

07/01/2016 Cimalgex - EMEA/V/C/000162 - R/0002

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Musculoskeletal system

Therapeutic indication

Relief of pain and inflammation associated with osteoarthritis.

Management of peri-operative pain due to orthopaedic or soft-tissue surgeries.

Assessment history

How useful was this page?

Add your rating